Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Gland Pharma is engaged in manufacturing small volume parenterals (SVPs) and contract development services.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has increased by 7.52%
1 day ago•The Hindu
1 day ago•Bloomberg Quint
1 day ago•Business Standard
Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ". | Download
Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ". | Download
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 6.03%